Checkpoint inhibitors and the risk of infection

References

• Curry WT, Lim M. Immunomodulation: checkpoint blockade etc. Neuro Oncol. 2015;17(Suppl 7):vii26–vii31.
   PubMed Web of Science ®Google Scholar
• Harter PN, Bernatz S, Scholz A, et al. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget. 2015;6(38):40836–40849.
   PubMed Web of Science ®Google Scholar
• Singh PP, Sharma PK, Krishnan G, et al. Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf). 2015;3(4):289–297.
   PubMed Web of Science ®Google Scholar
• Leshem Y, O’Brien J, Liu X, et al. Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anti-cancer immunity. Cancer Immunol Res. 2017;5(8):685–694.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy. 2015;7(11):1213–1227.
   PubMed Web of Science ®Google Scholar
• Khan U, Rizvi H, Sano D, et al. Nivolumab induced myxedema crisis. J Immunother Cancer. 2017;5:13.
   PubMed Web of Science ®Google Scholar
• Kim EY, Kim A, Kim SK, et al. MYC expression correlates with PD-L1 expression in non-small cell lung cancer. Lung Cancer. 2017;110:63–67.
   PubMed Web of Science ®Google Scholar
• Pike LRG, Bang A, Ott P, et al. Radiation and PD-1 inhibition: favorable outcomes after brain-directed radiation. Radiother Oncol. 2017;124(1):98–103.
   PubMed Web of Science ®Google Scholar
• Guo H, Tsung K. Tumor reductive therapies and antitumor immunity. Oncotarget. 2017;55:1109-1115.
   Web of Science ®Google Scholar
• Chikuma S. Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int J Clin Oncol. 2016;21(3):448–455.
   PubMed Web of Science ®Google Scholar
• Kähler KC, Hassel JC, Heinzerling L, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges. 2016;14(7):662–681.
   Web of Science ®Google Scholar
• Meunier F. Prevention and mycoses in immunocompromised patients. Rev Infect Dis. 1987;9(2):408–416.
   PubMedGoogle Scholar
• Kato Y, Otsuka A, Miyachi Y, et al. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol. 2016;30(10):e89–e91.
   PubMed Web of Science ®Google Scholar
• Turgeman I, Wollner M, Hassoun G, et al. Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab. Anticancer Drugs. 2017;28(7):811–814.
   PubMed Web of Science ®Google Scholar
• Lieben L. Immunotherapy: keeping breast cancer in check. Nat Rev Cancer. 2017;17(8):454–455.
   PubMed Web of Science ®Google Scholar
• Showalter A, Limaye A, Oyer JL, et al. Cytokines in immunogenic cell death: applications for cancer immunotherapy. Cytokine. 2017;97:123–132.
   PubMed Web of Science ®Google Scholar
• Morales A. BCG: a throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy. Can J Urol. 2017;24(3):8788–8793.
   PubMed Web of Science ®Google Scholar
• Dal Bello MG, Alama A, Coco S, et al. Understanding the checkpoint blockade in lung cancer immunotherapy. Drug Discov Today. 2017;22(8):1266–1273.
   PubMed Web of Science ®Google Scholar
• Kourie HR, Awada G, Awada A. The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. Immunotherapy. 2017;9(8):647–657.
   PubMed Web of Science ®Google Scholar
• Hu Y, Tian ZG, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 2017.
   Google Scholar
• Orentas RJ, Sindiri S, Duris C, et al. Paired expression analysis of tumor cell surface antigens. Front Oncol. 2017;7:173.
   PubMed Web of Science ®Google Scholar
• Walseng E, Köksal H, Sektioglu IM, et al. A TCR-based chimeric antigen receptor. Sci Rep. 2017;7(1):10713.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang DB, Shi H. Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy. Immunotherapy. 2017;9(10):851–861.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Oláh J. [Advances in immunotherapy for metastatic melanoma]. Magy Onkol. 2017;61(2):132–136.
   PubMedGoogle Scholar
• Kefford RF. Drug treatment for melanoma: progress, but who pays? Med J Aust. 2012;197(4):198–199.
   PubMed Web of Science ®Google Scholar
• Ishii H, Azuma K, Kawahara A, et al. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. Oncotarget. 2017.
   Web of Science ®Google Scholar
• Jelinek T, Mihalyova J, Kascak M, et al. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology. 2017;38:868-878.
   PubMed Web of Science ®Google Scholar
• Ni L, Dong C. New B7 family checkpoints in human cancers. Mol Cancer Ther. 2017;16(7):1203–1211.
   PubMed Web of Science ®Google Scholar
• Rao M, Valentini D, Dodoo E, et al. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis. 2017;56:221–228.
   PubMed Web of Science ®Google Scholar
• Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47(5):765–779.
   PubMed Web of Science ®Google Scholar
• Fujisawa Y, Yoshino K, Otsuka A, et al. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. J Dermatol Sci. 2017;3:211-219.
   Web of Science ®Google Scholar
• Hahn AW, Gill DM, Agarwal N, et al. PD-1 checkpoint inhibition: toxicities and management. Urol Oncol. 2017;18:321-351.
   Google Scholar
• Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–19.e10.
   PubMed Web of Science ®Google Scholar
• De Velasco G, Je Y, Bossé D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5(4):312–318.
   PubMed Web of Science ®Google Scholar
• Shah R, Witt D, Asif T, et al. Ipilimumab as a cause of severe pan-colitis and colonic perforation. Cureus. 2017;9(4):e1182.
   PubMedGoogle Scholar
• Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res. 2011;71(21):6567–6571.
   PubMed Web of Science ®Google Scholar
• Kurup SP, Obeng-Adjei N, Anthony SM, et al. Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4. Nat Med. 2017.
   PubMed Web of Science ®Google Scholar
• Shi L, Meng T, Zhao Z, et al. CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes. Gene. 2017;27:543-551.
   Google Scholar
• Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? Cancer J. 2010;16(4):311–317.
   PubMed Web of Science ®Google Scholar
• Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17):5591–5598.
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21(8):1712–1717.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–164.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Maráz A, Géczi L. [The role of immunotherapy in the modern treatment of urothelial carcinoma]. Magy Onkol. 2017;61(2):139–146. Hungarian
   PubMedGoogle Scholar
• Heinzerling L, Goldinger SM. A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin Oncol. 2017;29(2):136–144.
   PubMed Web of Science ®Google Scholar
• Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125–128.
   PubMed Web of Science ®Google Scholar
• Prieux-Klotz C, Dior M, Damotte D, et al. Immune checkpoint inhibitor-induced colitis: diagnosis and management. Target Oncol. 2017;12(3):301–308.
   PubMed Web of Science ®Google Scholar
• Fujita K, Terashima T, Mio T. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol. 2016;11(12):2238–2240.
   PubMed Web of Science ®Google Scholar
• Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;35:76–83.
   Google Scholar
• Del Castillo M, Romero FA, Argüello E, et al. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis. 2016;63(11):1490–1493.
   PubMed Web of Science ®Google Scholar
• Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505.
   PubMed Web of Science ®Google Scholar
• Dobler CC. Biologic agents and tuberculosis. Microbiol Spectr. 2016;4:6.
   Web of Science ®Google Scholar
• Abreu C, Afonso J, Dias CC, et al. Serial Tuberculosis screening in inflammatory bowel disease patients under anti-TNFα therapy. J Crohns Colitis. 2017.
   Web of Science ®Google Scholar
• Rana F, Shaikh MM, Bowles J. Listeria meningitis and resultant symptomatic hydrocephalus complicating infliximab treatment for ulcerative colitis. JRSM Open. 2014;5(3):2054270414522223.
   Google Scholar
• Dempke WCM, Fenchel K, Uciechowski P, et al. Targeting developmental pathways: the Achilles heel of cancer. Oncology. 2017.
   PubMed Web of Science ®Google Scholar
• Rudick CP, Cornell DL, Agrawal DK. Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis. Expert Rev Clin Immunol. 2017;51:1–13.
   PubMed Web of Science ®Google Scholar
• Chou S, Zhao C, Hwang SJE, et al. PD-1 inhibitor associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation - report of four cases. J Cutan Pathol. 2017;34:345-350.
   PubMed Web of Science ®Google Scholar
• Willis BC, Sloan EA, Atkins KA, et al. Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. Mod Pathol. 2017.
   PubMedGoogle Scholar
• Schwartz C, Khan AR, Floudas A, et al. ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control. J Exp Med. 2017;214(9):2507–2521.
   PubMed Web of Science ®Google Scholar
• Gao W, Zhou J, Ji B. Evidence of interleukin 21 reduction in osteosarcoma patients due to PD-1/PD-L1-mediated suppression of follicular helper T cell functionality. DNA Cell Biol. 2017.
   Web of Science ®Google Scholar
• Nukui A, Masuda A, Abe H, et al. Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy. BMC Cancer. 2017;17(1):372.
   PubMed Web of Science ®Google Scholar
• Overacre-Delgoffe AE, Chikina M, Dadey RE, et al. Interferon-γ drives treg fragility to promote anti-tumor immunity. Cell. 2017;169(6):1130–41.e11.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Meng X, Liu Y, Zhang J, et al. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: new development and challenges. Cancer Lett. 2017;405:29–37.
   PubMed Web of Science ®Google Scholar
• Røge R, Vyberg M, Nielsen S. Accurate PD-L1 protocols for non-small cell lung cancer can be developed for automated staining platforms with clone 22C3. Appl Immunohistochem Mol Morphol. 2017;25(6):381–385.
   PubMedGoogle Scholar
• Onizuka M, Kojima M, Matsui K, et al. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Int J Hematol. 2017;106(1):141–145.
   PubMed Web of Science ®Google Scholar
• Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;54:657-662.
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–792.
   PubMed Web of Science ®Google Scholar
• Adams JR, Angelotta C, Bennett CL. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? J Clin Oncol. 2006;24(19):2975–2977.
   PubMed Web of Science ®Google Scholar
• Bow EJ, Laverdière M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer. 2002;94(12):3230–3246.
   PubMed Web of Science ®Google Scholar
• Haderk F, Schulz R, Iskar M, et al. Tumor-derived exosomes modulate PD-L1 expression in monocytes. Sci Immunol. 2017;2:13.
   Web of Science ®Google Scholar
• Luo Q, Huang Z, Ye J, et al. PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus. Arthritis Res Ther. 2016;18:47.
   PubMed Web of Science ®Google Scholar
• Seeber A, Leitner C, Philipp-Abbrederis K, et al. What’s new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016. Future Oncol. 2017;13(16):1427–1435.
   PubMed Web of Science ®Google Scholar
• Kim ES. Avelumab: first global approval. Drugs. 2017;77(8):929–937.
   PubMed Web of Science ®Google Scholar
• Santini FC, Rudin CM. Atezolizumab for the treatment of non-small cell lung cancer. Expert Rev Clin Pharmacol. 2017;41:1–11.
   Web of Science ®Google Scholar
• Brower V. Atezolizumab in advanced non-small-cell lung cancer. Lancet Oncol. 2017;18(8):e434.
   PubMed Web of Science ®Google Scholar
• Spodzieja M, Lach S, Iwaszkiewicz J, et al. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses. PLoS One. 2017;12(6):e0179201.
   PubMed Web of Science ®Google Scholar
• Nakachi S, Sumitomo S, Tsuchida Y, et al. Interleukin-10-producing LAG3(+) regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):97.
   PubMed Web of Science ®Google Scholar
• Sergent PA, Plummer SF, Pettus J, et al. Blocking the VISTA pathway enhances disease progression in (NZB × NZW) F1 female mice. Lupus. 2017;25:961203317716322.
   PubMedGoogle Scholar
• Zhao D, Guo M, Liu B, et al. Frontline Science: tim-3-mediated dysfunctional engulfment of apoptotic cells in SLE. J Leukoc Biol. 2017;jlb.3HI0117-005RR.
   Google Scholar
• Rapoport BL, Van Eeden R, Sibaud V, et al. Supportive care for patients undergoing immunotherapy. Support Care Cancer. 2017;25(10):3017–3030.
   PubMed Web of Science ®Google Scholar
• Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261–1273.
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110(12):2614–2627.
   PubMed Web of Science ®Google Scholar
• Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014;2:19.
   PubMedGoogle Scholar
• Matsuki E, Younes A. Checkpoint inhibitors and other immune therapies for Hodgkin and non-Hodgkin lymphoma. Curr Treat Options Oncol. 2016;17(6):31.
   PubMed Web of Science ®Google Scholar
• Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, et al. Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors. Cancer Treat Rev. 2017;58:41–50.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Formenti SC, Demaria S. Towards precision radiotherapy for use with immune checkpoint blockers. Clin Cancer Res. 2017;clincanres.0037.2017.
   PubMedGoogle Scholar
• Baron M, Zini JM, Challan Belval T, et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leuk Lymphoma. 2017;68:1–2.
   Google Scholar
• Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833–43.e5.
   PubMed Web of Science ®Google Scholar
• Arthurs B, Wunderle K, Hsu M, et al. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep. 2017;21:27–29.
   PubMed Web of Science ®Google Scholar
• Chan TS, Au-Yeung R, Chim CS, et al. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia. Ann Hematol. 2017;96(5):871–872.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Proia LA, Demarais PL. Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis. 2016;2016:4642831.
   PubMedGoogle Scholar
• Messina JA, Maziarz EK, Spec A, et al. Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib. Open Forum Infect Dis. 2017;4(1):ofw261.
   PubMed Web of Science ®Google Scholar
• Demaria S, Bhardwaj N, McBride WH, et al. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63(3):655–666.
   PubMed Web of Science ®Google Scholar
• Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11(2 Pt 1):728–734.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Friedman CF, Wolchok JD. Combinatorial cancer immunotherapies. Adv Immunol. 2016;130:251–277.
   PubMed Web of Science ®Google Scholar
• Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377.
   PubMed Web of Science ®Google Scholar
• Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11(7):e0160221.
   PubMed Web of Science ®Google Scholar
• Karlsson AK, Saleh SN. Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. Clin Cosmet Investig Dermatol. 2017;10:325–339.
   PubMed Web of Science ®Google Scholar